Shockwave Medical, Inc. (NASDAQ:SWAV) Receives $309.11 Average PT from Analysts

Shares of Shockwave Medical, Inc. (NASDAQ:SWAV) have received a consensus rating of “Hold” from the eleven research firms that are covering the firm, Marketbeat.com reports. Ten investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $309.11.

A number of brokerages have issued reports on SWAV. TheStreet upgraded shares of Shockwave Medical from a “c+” rating to a “b” rating in a research note on Thursday, February 15th. Wolfe Research reiterated a “peer perform” rating on shares of Shockwave Medical in a research note on Friday, April 5th. Wells Fargo & Company upped their target price on Shockwave Medical from $200.00 to $210.00 and gave the company an “equal weight” rating in a report on Friday, February 16th. Leerink Partnrs cut Shockwave Medical from an “outperform” rating to a “market perform” rating in a report on Friday, April 5th. Finally, SVB Leerink restated a “market perform” rating and issued a $335.00 price objective (down from $361.00) on shares of Shockwave Medical in a report on Monday, April 8th.

Insider Buying and Selling

In related news, CFO Dan Puckett sold 3,406 shares of Shockwave Medical stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $229.76, for a total value of $782,562.56. Following the sale, the chief financial officer now directly owns 27,732 shares in the company, valued at $6,371,704.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, VP Trinh Phung sold 1,287 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $232.18, for a total value of $298,815.66. Following the completion of the sale, the vice president now owns 32,933 shares of the company’s stock, valued at $7,646,383.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dan Puckett sold 3,406 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $229.76, for a total transaction of $782,562.56. Following the completion of the transaction, the chief financial officer now owns 27,732 shares of the company’s stock, valued at $6,371,704.32. The disclosure for this sale can be found here. Insiders sold a total of 89,813 shares of company stock worth $22,863,919 in the last 90 days. Company insiders own 3.40% of the company’s stock.

Institutional Trading of Shockwave Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Robbins Farley raised its holdings in shares of Shockwave Medical by 1.0% during the fourth quarter. Robbins Farley now owns 4,542 shares of the company’s stock valued at $866,000 after buying an additional 45 shares during the last quarter. Parallel Advisors LLC grew its position in Shockwave Medical by 3.8% in the fourth quarter. Parallel Advisors LLC now owns 1,268 shares of the company’s stock worth $242,000 after acquiring an additional 47 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Shockwave Medical by 11.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 483 shares of the company’s stock valued at $96,000 after acquiring an additional 50 shares during the last quarter. Lindbrook Capital LLC lifted its stake in shares of Shockwave Medical by 64.8% in the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after buying an additional 59 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its holdings in Shockwave Medical by 0.4% in the 3rd quarter. Treasurer of the State of North Carolina now owns 16,390 shares of the company’s stock valued at $3,263,000 after buying an additional 60 shares during the last quarter. Institutional investors own 95.35% of the company’s stock.

Shockwave Medical Trading Down 0.1 %

Shares of SWAV stock opened at $329.51 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 11.76 and a quick ratio of 10.73. The stock’s 50 day simple moving average is $296.22 and its two-hundred day simple moving average is $234.65. The company has a market cap of $12.32 billion, a PE ratio of 85.14, a price-to-earnings-growth ratio of 2.45 and a beta of 0.92. Shockwave Medical has a 1 year low of $157.00 and a 1 year high of $331.58.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings data on Thursday, February 15th. The company reported $1.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.24. The company had revenue of $202.98 million during the quarter, compared to analysts’ expectations of $199.43 million. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. Shockwave Medical’s revenue was up 41.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.71 EPS. Research analysts predict that Shockwave Medical will post 4.94 earnings per share for the current year.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.